Role of proteoglycans in the regulation of the skeletal muscle fibrotic response

FEBS Journal

Volumn 280, Issue 17, 2013, Pages 4109-4117

  Brandan, Enrique ^a   Gutierrez, Jaime ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

connective tissue growth factor (CTGF); fibrosis; muscular diseases; proteoglycans; transforming growth factor (TGF )

Indexed keywords

BIGLYCAN; CELL SURFACE RECEPTOR; CHONDROITIN; CONNECTIVE TISSUE GROWTH FACTOR; CREATINE KINASE; DECORIN; DERMATAN SULFATE; HSPG BETA GLYCAN; LEUCINE RICH REPEAT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MYOSIN; MYOSTATIN; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; CELL ADHESION; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; MUSCLE DEVELOPMENT; MUSCLE INJURY; MYOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVIEW; SCAR FORMATION; SKELETAL MUSCLE; WOUND HEALING;

CONNECTIVE TISSUE GROWTH FACTOR (CTGF); FIBROSIS; MUSCULAR DISEASES; PROTEOGLYCANS; TRANSFORMING GROWTH FACTOR-Β (TGF-Β);

ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; FIBROSIS; HUMANS; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; PROTEOGLYCANS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84882596804     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12278     Document Type: Review

References (98)

1. Iozzo RV, &, Schaefer L, (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864-3875.
2. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
3. Brandan E, Cabello-Verrugio C, &, Vial C, (2008) Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 27, 700-708.
4. Iozzo RV, (1999) The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 274, 18843-18846.
5. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, &, Zako M, (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777.
6. Jenniskens GJ, Veerkamp JH, &, van Kuppevelt TH, (2006) Heparan sulfates in skeletal muscle development and physiology. J Cell Physiol 206, 283-294.
7. Filmus J, Capurro M, &, Rast J, (2008) Glypicans. Genome Biol 9, 224, doi: 10.1186/gb-2008-9-5-224.
8. Iozzo RV, &, Schaefer L, (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864-3875.
9. Gillies AR, &, Lieber RL, (2011) Structure and function of the skeletal muscle extracellular matrix. Muscle Nerve 44, 318-331.
10. Iozzo RV, &, Karamanos N, (2010) Proteoglycans in health and disease: emerging concepts and future directions. FEBS J 277, 3863, doi: 10.1111/j.1742-4658.2010.07796.x.
11. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, &, Munoz-Canoves P, (2011) Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle 1, 21, doi: 10.1186/2044-5040-1-21.
12. Fadic R, Mezzano V, Alvarez K, Cabrera D, Holmgren J, &, Brandan E, (2006) Increase in decorin and biglycan in Duchenne muscular dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease. J Cell Mol Med 10, 758-769.
13. Porter JD, Merriam AP, Leahy P, Gong B, Feuerman J, Cheng G, &, Khanna S, (2004) Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Hum Mol Genet 13, 257-269.
14. Reed P, &, Bloch RJ, (2005) Postnatal changes in sarcolemmal organization in the mdx mouse. Neuromuscul Disord 15, 552-561.
15. Serrano AL, &, Munoz-Canoves P, (2010) Regulation and dysregulation of fibrosis in skeletal muscle. Exp Cell Res 316, 3050-3058.
16. Alvarez K, Fadic R, &, Brandan E, (2002) Augmented synthesis and differential localization of heparan sulfate proteoglycans in Duchenne muscular dystrophy. J Cell Biochem 85, 703-713.
17. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De Mori R, Baeza-Raja B, Martinez de Lagran M, Lafuste P, Ruiz-Bonilla V, et al,. (2008) Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 22, 1747-1752.
18. Wynn TA, (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214, 199-210.
19. Leask A, (2009) Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite Ed) 1, 115-122.
20. Bernasconi P, Di Blasi C, Mora M, Morandi L, Galbiati S, Confalonieri P, Cornelio F, &, Mantegazza R, (1999) Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscul Disord 9, 28-33.
21. Hartel JV, Granchelli JA, Hudecki MS, Pollina CM, &, Gosselin LE, (2001) Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. Muscle Nerve 24, 428-432.
22. Sun G, Haginoya K, Wu Y, Chiba Y, Nakanishi T, Onuma A, Sato Y, Takigawa M, Iinuma K, &, Tsuchiya S, (2008) Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J Neurol Sci 267, 48-56.
23. Morales G, Cabello-Verrugio C, Cabrera D, Goldschmeding R, &, Brandan E, (2011) CTGF/CCN-2 overexpression can directly induce features of skeletal muscle dystrophy. J Pathol 225, 490-501.
24. Passerini L, Bernasconi P, Baggi F, Confalonieri P, Cozzi F, Cornelio F, &, Mantegazza R, (2002) Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscul Disord 12, 828-835.
25. Porter JD, Merriam AP, Leahy P, Gong B, &, Khanna S, (2003) Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet 12, 1813-1821.
26. Riquelme C, Larrain J, Schonherr E, Henriquez JP, Kresse H, &, Brandan E, (2001) Antisense inhibition of decorin expression in myoblasts decreases cell responsiveness to transforming growth factor beta and accelerates skeletal muscle differentiation. J Biol Chem 276, 3589-3596.
27. Massague J, Cheifetz S, Endo T, &, Nadal-Ginard B, (1986) Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci USA 83, 8206-8210.
28. Massague J, (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1, 169-178.
29. Derynck R, &, Zhang YE, (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584.
30. Brigstock DR, (1999) The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 20, 189-206.
31. Leask A, &, Abraham DJ, (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119, 4803-4810.
32. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, &, Takehara K, (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106, 729-733.
33. Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, Marz W, Rupp J, Pech M, &, Luscher TF, (1997) Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 95, 831-839.
34. Lasky JA, Ortiz LA, Tonthat B, Hoyle GW, Corti M, Athas G, Lungarella G, Brody A, &, Friedman M, (1998) Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 275, L365-371.
35. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, &, Goldschmeding R, (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53, 853-861.
36. di Mola FF, Friess H, Martignoni ME, Di Sebastiano P, Zimmermann A, Innocenti P, Graber H, Gold LI, Korc M, &, Buchler MW, (1999) Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg 230, 63-71.
37. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, Ba N, Sobesky R, Ratziu V, et al,. (1999) Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30, 968-976.
38. Caceres S, Cuellar C, Casar JC, Garrido J, Schaefer L, Kresse H, &, Brandan E, (2000) Synthesis of proteoglycans is augmented in dystrophic mdx mouse skeletal muscle. Eur J Cell Biol 79, 173-181.
39. Schiaffino S, &, Partridge T, (2008) Skeletal muscle repair and regeneration. In Advances in Muscle Research Vol. 3 (, Stienen, GJM, ed), pp. 379. Springer, New York.
40. Bowe M, Mendis D, &, Fallon J, (2000) The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. J Cell Biol 148, 801-810.
41. Zanotti S, Negri T, Cappelletti C, Bernasconi P, Canioni E, Di Blasi C, Pegoraro E, Angelini C, Ciscato P, Prelle A, et al,. (2005) Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 128, 2546-2555.
42. Fadic R, (2005) Cell surface and gene expression regulation molecules in dystrophinopathy: mdx vs. Duchenne. Biol Res 38, 375-380.
43. Mezzano V, Cabrera D, Vial C, &, Brandan E, (2007) Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2. J Cell Commun Signal 1, 205-217.
44. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS, &, Fallon JR, (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 108, 762-767.
45. Droguett R, Cabello-Verrugio C, Riquelme C, &, Brandan E, (2006) Extracellular proteoglycans modifies TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol 25, 332-341.
46. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, &, Martinez DA, (2004) Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30, 645-653.
47. Huang G, &, Brigstock DR, (2011) Integrin expression and function in the response of primary culture hepatic stellate cells to connective tissue growth factor (CCN2). J Cell Mol Med 15, 1087-1095.
48. Chen CC, &, Lau LF, (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41, 771-783.
49. Gao R, &, Brigstock DR, (2003) Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol Res 27, 214-220.
50. Vial C, Zuniga LM, Cabello-Verrugio C, Canon P, Fadic R, &, Brandan E, (2008) Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation. J Cell Physiol 215, 410-421.
51. Vial C, Gutiérrez J, Santander C, Cabrera D, &, Brandan E, (2011) Decorin interacts with CTGF/CCN2 through LRR12 inhibiting its biological activity. J Biol Chem 286, 24242-24252.
52. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, &, Haase VH, (2004) Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 287, F1223-F1232.
53. Hafizi S, Wharton J, Chester A, &, Yacoub M, (2004) Profibrotic effects of endothelin-1 via the ET(A) receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem 14, 285-292.
54. Pereira RM, dos Santos RA, da Costa Dias FL, Teixeira MM, &, Simoes e Silva AC, (2009) Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol 15, 2579-2586.
55. Pohlers D, Brenmoehl J, Loffler I, Muller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, &, Wolf G, (2009) TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 1792, 746-756.
56. Shi-Wen X, Leask A, &, Abraham D, (2008) Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 19, 133-144.
57. Ardite E, Perdiguero E, Vidal B, Gutarra S, Serrano AL, &, Munoz-Canoves P, (2012) PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J Cell Biol 196, 163-175.
58. Ishitobi M, Haginoya K, Zhao Y, Ohnuma A, Minato J, Yanagisawa T, Tanabu M, Kikuchi M, &, Iinuma K, (2000) Elevated plasma levels of transforming growth factor beta1 in patients with muscular dystrophy. NeuroReport 11, 4033-4035.
59. Murakami N, McLennan IS, Nonaka I, Koishi K, Baker C, &, Hammond-Tooke G, (1999) Transforming growth factor-beta2 is elevated in skeletal muscle disorders. Muscle Nerve 22, 889-898.
60. Sun G, Haginoya K, Wu Y, Chiba Y, Nakanishi T, Onuma A, Sato Y, Takigawa M, Iinuma K, &, Tsuchiya S, (2007) Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J Neurol Sci 267, 48-56.
61. Li Y, Li J, Zhu J, Sun B, Branca M, Tang Y, Foster W, Xiao X, &, Huard J, (2007) Decorin gene transfer promotes muscle cell differentiation and muscle regeneration. Mol Ther 15, 1616-1622.
62. Taniguti AP, Pertille A, Matsumura CY, Santo Neto H, &, Marques MJ, (2011) Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker. Muscle Nerve 43, 82-87.
63. Pistilli EE, Bogdanovich S, Goncalves MD, Ahima RS, Lachey J, Seehra J, &, Khurana T, (2011) Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol 178, 1287-1297.
64. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, &, Pines M, (2008) Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord 18, 857-868.
65. Fukushima K, Badlani N, Usas A, Riano F, Fu F, &, Huard J, (2001) The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29, 394-402.
66. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, &, Huard J, (2004) Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 164, 1007-1019.
67. Sato K, Li Y, Foster W, Fukushima K, Badlani N, Adachi N, Usas A, Fu FH, &, Huard J, (2003) Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis. Muscle Nerve 28, 365-372.
68. Zhu J, Li Y, Shen W, Qiao C, Ambrosio F, Lavasani M, Nozaki M, Branca MF, &, Huard J, (2007) Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. J Biol Chem 282, 25852-25863.
69. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, &, Ruoslahti E, (1994) Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302, 527-534.
70. Schonherr E, Broszat M, Brandan E, Bruckner P, &, Kresse H, (1998) Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen. Arch Biochem Biophys 355, 241-248.
71. Iozzo RV, (1997) The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32, 141-174.
72. Brandan E, Fuentes ME, &, Andrade W, (1991) The proteoglycan decorin is synthesized and secreted by differentiated myotubes. Eur J Cell Biol 55, 209-216.
73. Florini JR, Ewton DZ, &, Magri KA, (1991) Hormones, growth factors, and myogenic differentiation. Annu Rev Physiol 53, 201-216.
74. Cabello-Verrugio C, &, Brandan E, (2007) A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J Biol Chem 282, 18842-18850.
75. Cabello-Verrugio C, Santander C, Cofre C, Acuna MJ, Melo F, &, Brandan E, (2012) The internal region leucine-rich repeat 6 of decorin interacts with low density lipoprotein receptor-related protein-1, modulates transforming growth factor (TGF)-beta-dependent signaling, and inhibits TGF-beta-dependent fibrotic response in skeletal muscles. J Biol Chem 287, 6773-6787.
76. Brandan E, Retamal C, Cabello-Verrugio C, &, Marzolo MP, (2006) The low density lipoprotein receptor-related protein functions as an endocytic receptor for decorin. J Biol Chem 281, 31562-31571.
77. Miura T, Kishioka Y, Wakamatsu J, Hattori A, Hennebry A, Berry CJ, Sharma M, Kambadur R, &, Nishimura T, (2006) Decorin binds myostatin and modulates its activity to muscle cells. Biochem Biophys Res Commun 340, 675-680.
78. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, Sharma M, &, Kambadur R, (2005) Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118, 3531-3541.
79. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, &, Lopez-Casillas F, (2001) Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem 276, 14588-14596.
80. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, &, Massague J, (1991) Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67, 785-795.
81. Santander C, &, Brandan E, (2006) Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. Cell Signal 18, 1492-1491.
82. Cabello-Verrugio C, Morales G, Cabrera D, Vio CP, &, Brandan E, (2011) Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J Cell Mol Med 16, 752-764.
83. Yoshida K, &, Munakata H, (2007) Connective tissue growth factor binds to fibronectin through the type I repeat modules and enhances the affinity of fibronectin to fibrin. Biochim Biophys Acta 1770, 672-680.
84. Abreu JG, Ketpura NI, Reversade B, &, De Robertis EM, (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 4, 599-604.
85. Wahab NA, Weston BS, &, Mason RM, (2005) Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 16, 340-351.
86. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR III, &, Carmichael DF, (2001) The low density lipoprotein receptor-related protein/alpha2- macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 276, 40659-40667.
87. Mason RM, (2013) Fell-Muir lecture: connective tissue growth factor (CCN2)-a pernicious and pleiotropic player in the development of kidney fibrosis. Int J Exp Pathol 94, 1-16.
88. Droppelmann C, Gutierrez J, Vial C, &, Brandan E, (2009) MMP-2 deficient fibroblasts exhibit an alteration in the fibrotic response to CTGF/CCN2 due to an increase in the levels of endogenous fibronectin. J Biol Chem 284, 13551-13561.
89. Bornstein P, &, Sage EH, (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14, 608-616.
90. Cicha I, &, Goppelt-Struebe M, (2009) Connective tissue growth factor: context-dependent functions and mechanisms of regulation. BioFactors 35, 200-208.
91. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, Zhou H, Lu H, &, Jin Y, (2006) Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 8, 889-900.
92. Guha M, Xu ZG, Tung D, Lanting L, &, Natarajan R, (2007) Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21, 3355-3368.
93. Sisco M, Kryger ZB, O'Shaughnessy KD, Kim PS, Schultz GS, Ding XZ, Roy NK, Dean NM, &, Mustoe TA, (2008) Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair Regen 16, 661-673.
94. Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, Brenner M, Guo G, Zhang W, Oliver N, et al,. (2011) Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4, 4, doi: 10.1186/1755-1536-4-4.
95. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB, Urquilla PR, &, Sewell KL, (2010) Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5, 1420-1428.
96. Leask A, (2011) CCN2/decorin interactions: a novel approach to combating fibrosis? J Cell Commun Signal 5, 249-250.
97. Segarini P, Roberts A, Rosen D, &, Seyedin S, (1987) Membrane binding characteristics of two forms of transforming growth factor-beta. J Biol Chem 262, 14655-14662.
98. Wilsie LC, &, Orlando RA, (2003) The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism. J Biol Chem 278, 15758-15764.